Chen L, Gan X T, Haist J V, Feng Q, Lu X, Chakrabarti S, Karmazyn M
Department of Pharmacology and Toxicology, University of Western Ontario, London, Ontario, Canada.
J Pharmacol Exp Ther. 2001 Aug;298(2):469-76.
Pulmonary hypertension results in compensatory right ventricular (RV) hypertrophy. We studied the role of the Na+-H+ exchange (NHE) in the latter process by determining the effect of the NHE-1 inhibitor cariporide after monocrotaline-induced pulmonary artery injury. Sprague-Dawley rats received a control or cariporide diet for 7 days, at which time they were administered either monocrotaline (60 mg/kg) or its vehicle. Twenty-one days later, monocrotaline control, but not cariporide-fed animals, demonstrated increased RV weights and cell size of 65 and 52%, respectively. Monocrotaline alone significantly increased RV systolic pressure and end diastolic pressure by 70 and 94%, respectively, whereas corresponding values with cariporide were significantly reduced to 33 and 42%. Central venous pressure increased by 414% in control animals, which was significantly reduced by cariporide. Monocrotaline treatment produced a decrease in cardiac output of 28 and 8% in the absence or presence of cariporide (P < 0.05 between groups), respectively. Although body weights were significantly lower in both monocrotaline-treated groups compared with vehicle treatment, with cariporide the net gain in body weight was twice that seen in the monocrotaline-treated animals without cariporide. Monocrotaline also increased RV NHE-1 and atrial natriuretic peptide mRNA expression, which was abrogated by cariporide. Monocrotaline-induced myocardial necrosis, fibrosis, and mononuclear infiltration was completely prevented by cariporide. Cariporide had no effect on monocrotaline-induced pulmonary intimal wall thickening. Our results demonstrate that cariporide directly attenuates myocardial dysfunction after monocrotaline administration independent of pulmonary vascular effects. NHE-1 inhibition may represent an effective adjunctive therapy that selectively targets myocardial hypertrophic responses in pulmonary vascular injury.
肺动脉高压会导致右心室(RV)代偿性肥厚。我们通过测定NHE-1抑制剂卡立泊来在野百合碱诱导的肺动脉损伤后的作用,研究了NHE在这一过程中的作用。Sprague-Dawley大鼠接受对照或卡立泊来饮食7天,此时给予它们野百合碱(60mg/kg)或其溶剂。21天后,野百合碱对照组而非给予卡立泊来的动物,分别显示右心室重量和细胞大小增加了65%和52%。单独使用野百合碱分别使右心室收缩压和舒张末期压力显著增加70%和94%,而卡立泊来组的相应值显著降低至33%和42%。对照动物的中心静脉压增加了414%,卡立泊来使其显著降低。在有无卡立泊来的情况下,野百合碱治疗分别使心输出量降低28%和8%(两组间P<0.05)。尽管与溶剂治疗相比,两个野百合碱治疗组的体重均显著降低,但使用卡立泊来的动物体重净增加是未使用卡立泊来的野百合碱治疗动物的两倍。野百合碱还增加了右心室NHE-1和心房利钠肽mRNA表达,卡立泊来可消除这种增加。卡立泊来完全预防了野百合碱诱导的心肌坏死、纤维化和单核细胞浸润。卡立泊来对野百合碱诱导的肺内膜壁增厚没有影响。我们的结果表明,卡立泊来在给予野百合碱后可直接减轻心肌功能障碍,且与肺血管效应无关。抑制NHE-1可能代表一种有效的辅助治疗方法,可选择性地针对肺血管损伤中的心肌肥厚反应。